-
Roche's PD-L1+TIGIT dual target is used in the first-line NSCLC treatment, the effect is amazing, and the risk of OS death is reduced by 71%
Time of Update: 2021-12-24
On December 10, Roche announced the latest data on the PD-L1 antibody + TIGIT antibody combined with the first-line treatment of NSCLC Phase II clinical CITYSCAPE .
-
BMC Cancer: Two-drug versus three-drug neoadjuvant treatment of locally advanced gastric cancer (LAGC): a study of propensity score matching (PSM)
Time of Update: 2021-12-24
Recently, a team from the Sixth Affiliated Hospital of Sun Yat-sen University conducted a related retrospective study to evaluate the efficacy of three-drug versus dual-drug neoadjuvant (NAC) in the treatment of locally advanced gastric cancer (LAGC) patients .
-
Nature: CLIP1-LTK, a new target for non-small cell lung cancer was discovered, and loratinib works well
Time of Update: 2021-12-24
The transformation activity of CLIP1-LTK fusion in vivo (Source: Nature)Thanks to the above results, looking for kinase inhibitors of CLIP1-LTK protein will have clinical therapeutic significance .
Nature (2021)1 The CLIP1-LTK fusion is an oncogenic driver in non-small-cell lung cancer.
-
J Urol: Can the Geriatric Nutritional Risk Index (GNRI) predict postoperative complications of bladder cancer?
Time of Update: 2021-12-24
Patient selection flowchartPatient selection flowchartIn summary, GNRI is a standardized nutritional status screening tool that can be used to pre-operatively assess the risk of postoperative complications in elderly patients undergoing RC surgery, as well as mortality, pneumonia, blood transfusion, prolonged hospital stay, and non-family discharge Independent predictors .
-
Clin Cancer Res: Efficacy of the PARP inhibitor Pamiparib as a single agent in the treatment of platinum-sensitive/resistant ovarian cancer
Time of Update: 2021-12-24
Pamiparib 60 mg bid showed longer-lasting anti-tumor activity in patients with platinum-sensitive ovarian cancer or platinum-resistant ovarian cancer carrying gBRCAmut.
Pamiparib Monotherapy for Patients With Germline BRCA1/2-Mutated Ovarian Cancer Previously Treated With at Least Two Lines of Chemotherapy: A Multicenter, Open-Label, Phase II Study .
-
BJU Int: Should patients with non-muscular invasive bladder cancer stop using fibrin clot inhibitors during BCG?
Time of Update: 2021-12-24
Recently, researchers from the United States published an article in "BJU Int" to determine the impact of FCI on oncology results in a cohort of patients with non-muscular invasive bladder cancer (NMIBC) who received adequate BCG therapy .
-
BMJ: Remote active toxicity management during chemotherapy for breast cancer patients can reduce the risk of chemotherapy adverse events
Time of Update: 2021-12-24
Remote active toxicity management during chemotherapy for early-stage breast cancer patients can reduce the number of emergency visits or hospitalizations caused by adverse chemotherapy events .
Remote active toxicity management during chemotherapy for early breast cancer patients can reduce the number of emergency visits or hospitalizations caused by adverse chemotherapy events .
-
[Gut Microbes] Why is the "king of cancer" pancreatic cancer so difficult to treat? It turns out that anticancer drugs are secretly eaten by bacteria!
Time of Update: 2021-12-05
Reducing the effects of cytostatics The link between IPMNs and pancreatic cancer is not fully understood, but early studies at the Karolinska Institute and elsewhere have shown that the presence of oral bacteria in the pancreas may be a measure of the severity of IPMN lesions Indicators .
-
Science Sub-Journal: New anti-cancer mechanism of paclitaxel!
Time of Update: 2021-12-05
04Tumor Life Passage The whole process of real demonstration of internal jugular venous catheter placement is worth collecting!
Long press the QR code to follow us The latest tumor information is waiting for you!
-
Sub-Journal of "Nature": Cancer cells "sneak" on T cells!
Time of Update: 2021-12-05
For the first time, researchers discovered that cancer cells actually "stole" immune cells through nanotube structures between cells.
This is the first time it has been discovered that cancer cells can steal mitochondria from immune cells through nanotubes!
-
EMBO J Cancer Review 2021: The molecular, cellular and tissue origins of cancer
Time of Update: 2021-12-05
The EMBO Journal Cancer Review 2021 Welcome to scan the code to read this series of review papers containing articles published in The EMBO Journal in 2021, covering all aspects of tumor biology, including hypoxia, cancer evolution, and the role of metabolism in the tumor microenvironment , Cellular senescence, RNA translation regulation, cell communication through extracellular vesicles, autophagy, etc.
-
What is the impact of the inherent EGFR gene mutation on the targeted therapy of lung cancer?
Time of Update: 2021-12-05
The median progression-free survival time of EGFR-targeted drug therapy is four months, which is much shorter than that of patients without EGFR blast cell mutations .
Some patients used the first-generation EGFR-targeted drug gefitinib in second-line treatment, and the median progression-free survival time was only 8 months .
-
Express treatment of specific lung cancer patients, Hutchison Medicine and AstraZeneca initiate phase 3 clinical trials of combination therapy in China
Time of Update: 2021-12-05
The trial will be carried out in lung cancer patients with EGFR and MET mutations or abnormalities who have relapsed after receiving EGFR inhibitor treatment, and aims to evaluate highly selective and potent oral mesenchymal transition factor (MET) tyrosine kinase inhibitors (TKI) Orpathys, the efficacy and safety of the combination with AstraZeneca’s third-generation irreversible epidermal growth factor receptor (EGFR) TKI Tagrisso .
-
Will dyeing hair cause cancer? More and more studies have found that the risk of these cancers will increase
Time of Update: 2021-12-05
In 2019, a study published in the International Journal of Cancer found that the use of permanent hair dyes and hair straighteners was associated with an increased risk of breast cancer in women .
-
Sub-Journal of The Lancet: Is immunotherapy administered during the day or at night?
Time of Update: 2021-12-05
Recently, The Lancet Oncology published a study that the time for melanoma patients to receive immunotherapy has a certain impact on the survival of patients, and PD-1 inhibitors may be best injected before 4:30 in the afternoon [3] .
-
Low-level "markers" prompt: better outcomes for advanced kidney cancer
Time of Update: 2021-12-05
This study conducted a retrospective analysis of the results of the first interim analysis of the Phase III JAVELIN Renal 101 study, and evaluated the baseline NLR levels and progression-free survival (PFS) in the avirumumab+axitinib group and the sunitinib group.
-
For the first time in complete remission, Aptevo shows new positive clinical data for targeting CD123xCD3 double antibodies, Yi Mai Meng broke the news
Time of Update: 2021-12-05
APVO436 is a bispecific antibody targeting CD123 and CD3 The candidate product is currently being evaluated for efficacy and safety in the treatment of acute myeloid leukemia (AML) .
-
The world's first subcutaneous PD-L1 envolimab is approved for marketing in China
Time of Update: 2021-12-05
Recently, according to the latest announcement by the National Medical Products Administration (NMPA) of China, Corning Jereh, Siddi Medicine, and Simcere Pharmaceuticals have reached a strategic cooperation with Class 1 biological drug Envolimab Injection (KN035) that has been qualified.
-
Teriplizumab has a new indication, osimertinib + bevacizumab failed to bring benefits to drug-resistant patients
Time of Update: 2021-12-05
(If you need the original text of the literature, you can add the editor WeChat yxj_oncology to obtain it) Key points: Annals of Oncology: Osimertinib combined with bevacizumab failed to give epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) ) Treatment failure patients bring survival benefits NEJM: Hypoxia-inducible factor-2α (HIF-2α) inhibitor Belzutifan in the treatment of Von Hippel-Lindau (VHL) syndrome-associated renal cell carcinoma (RCC) has a gratifying effect.
-
100% objective relief?
Time of Update: 2021-12-05
In May of this year, the MD Anderson Cancer Center of the University of Texas in the United States published the latest research results in Clinical Cancer Research of the American Association for Cancer Research, showing that cytokine-activated donor cord blood-derived natural killer (cbNK) cells combine to target CD16a and The CD30 research bispecific antibody AFM13 has strong anti-tumor activity against CD30+ lymphoma cells .
